REGENXBIO Inc. (RGNX)
D
Pipeline Grade
Financial Position (from SEC Filings)
$17.3M
Cash & Equivalents
$76.2M
Quarterly Burn Rate
1 mo
Est. Cash Runway
$721M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2026-08-01 | Phase2 Readout | — |
| 2026-08-01 | Phase3 Readout | — |
| 2026-10-01 | Phase3 Readout | — |
| 2026-12-01 | Phase3 Readout | — |
Active Clinical Trials (11)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT06103487 | Long Term Follow-Up for RGX-111 | OTHER | Enrolling By Invitation | 21 |
| NCT05683379 | AFFINITY BEYOND: Anti-AAV8 Antibody Assessment Study of Males With DMD | OTHER | Active Not Recruiting | 200 |
| NCT06491927 | Long Term Follow-up for RGX-202 | OTHER | Enrolling By Invitation | 66 |
| NCT05407636 | Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD | PHASE3 | Recruiting | 714 |
| NCT04704921 | Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Pa... | PHASE3 | Active Not Recruiting | 671 |
| NCT07236606 | RGX-121-3102 Gene Therapy in Participants With MPS II (Hunter Syndrome) | PHASE3 | Active Not Recruiting | 2 |
| NCT03566043 | CAMPSIITE™ RGX-121 Gene Therapy in Subjects With MPS II (Hunter Syndrome) | PHASE3 | Active Not Recruiting | 48 |
| NCT05693142 | AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscular Dystrophy (DMD) | PHASE3 | Recruiting | 65 |
| NCT06942520 | Phase 2 Trial of RGX-314 in Adults With Center Involved - Diabetic Macular Edema (CI - DME) | PHASE2 | Recruiting | 18 |
| NCT04567550 | RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Diabetic Retinopathy (DR) With and W... | PHASE2 | Active Not Recruiting | 139 |
| NCT04514653 | RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Dege... | PHASE2 | Active Not Recruiting | 146 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.